To date, two Gadolinium-based hepatobiliary agents have been approved by the FDA. While these agents show different principal characteristics such as rates of biliary excretion in rats and paramagnetic properties in in vitro studies at different magnetic field strengths, little is known about their clinical efficacy at a magnetic field strength of 3T. Therefore, it is the aim of this study to investigate the clinical efficacy and specific differences of Gadoxetic Acid Disodium (Gd-EOB-DTPA, Eovist(TM)) and Gadobenate Dimeglumin (Gd-BOPTA, MultiHance(TM)) in a cross-over study in volunteers at 3T with the analysis of the optimal flip angle for structure differentiation.
September 2009 to October 2009
This project led by: Scott B Reeder, MD, PhD